Lv4
760 积分 2022-09-28 加入
Development of a physiologically based pharmacokinetic (PBPK) model of psilocybin and psilocin from magic mushroom in rats and humans
3小时前
待确认
Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M4 Muscarinic Acetylcholine Receptor
4天前
已完结
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial
5天前
已完结
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial
5天前
已完结
Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1
19天前
已完结
In Vitro-In Vivo Extrapolation and Scaling Factors for Clearance of Human and Preclinical Species with Liver Microsomes and Hepatocytes
1个月前
已完结
Concentration–response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent
1个月前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
1个月前
已完结
Muscarinic control of cardiovascular function in humans: a review of current clinical evidence
1个月前
已完结
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial
1个月前
已完结
皖公网安备34019202002308
